The astroglial protein S100B and visually evoked event-related potentials before and after antidepressant treatment
S100B is an astrocytic, calcium-binding protein which in nanomolar concentrations has neuroprotective and regenerating effects on neurons and glial cells. Increased levels have been shown to be positively correlated with therapeutic response in major depression. Event-related potentials (ERP) have been reported to be impaired in depressed patients.
The aim of our study was to assess the relationship between S100B and visually evoked ERP in depression.
ERP and S100B serum concentration were studied in 18 patients with major depression, before and after 4 weeks of antidepressant treatment.
The S100B concentration in patients was increased at intake and after 4 weeks of treatment compared to healthy controls. Initially increased P3-latency normalized and P2-latency significantly decreased after 4 weeks of treatment, although only in patients with clearly elevated initial S100B levels (mean plus 2 SD of the healthy controls).
The neuroregenerative activity of moderately increased S100B levels in major depression might be a factor contributing to a decrease of prolonged ERP parameters in major depression during antidepressant treatment.
KeywordsS100B Major depression Event-related potentials Reboxetine Citalopram
- Dietrich DE, Hauser U, Peters M, Zhang Y, Wiesmann M, Hasselmann M, Rudolf S, Jüngling O, Kirchner H, Münte T, Arolt V, Emrich HM, Sönke J, Rothermundt M (2004) Target evaluation processing correlates with serum levels of nerve tissue protein S100B in patients with remitted major depression. Neurosci Lett 354:69–73CrossRefPubMedGoogle Scholar
- Hetzel G, Moeller O, Erfurth A, Michael N, Rothermundt M, Arolt V, Evers S (2004) The impact of the selective monoamine reuptake inhibitors reboxetine and citalopram on visually-evoked event-related potentials in depressed patients. Pharmacopsychiatry (in press)Google Scholar
- Himani A, Tandon OP, Bhatia MS (1999) A study of P300-event related evoked potential in the patients of major depression. Ind J Physiol Pharmacol 43:367–372Google Scholar
- Mulert C, Juckel G, Augustin H, Hegerl U (2002) Comparison between the analysis of the loudness dependency of the auditory N1/P2 component with LORETA and dipole source analysis in the prediction of treatment response to the selective reuptake inhibitor citalopram in major depression. Clin Neurophysiol 113:1566–1572CrossRefPubMedGoogle Scholar
- Rothermundt M, Ponath G, Glaser T, Hetzel G, Arolt V (2004) S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia. Neuropsychopharmacology (in press). Advance online publication DOI 10.1038/sj.npp.1300403
- Wittchen H-O, Pfister H (1997) Diagnostisches expertensystem für psychische Störungen DIA-X. SWETS Test Services, FrankfurtGoogle Scholar